Cardio Diagnostics Holdings, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Cardio Diagnostics Holdings, Inc. (CDIO) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $476.07 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-07
- Cardio Diagnostics Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $1.97M, a 5.65% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $1.86M, a 565.64% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $279.62K, a 89.21% decline year-over-year.
- Cardio Diagnostics Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $2.59M.
- Cardio Diagnostics Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$2.72M, a 141.52% decline from fiscal 2024.
- Cardio Diagnostics Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $6.54M.
- Cardio Diagnostics Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$2.83M, a 178.62% decline from fiscal 2022.
- Cardio Diagnostics Holdings, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $3.60M, a 1207.59% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 1 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 4 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 7 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $476.07K 10-Q · filed 2026-08-07 | ||||||||||
| 2026-03-31 | $1.97M 10-Q · filed 2026-05-15 | ||||||||||
| 2025-12-31 | -$2.72M 10-K · filed 2026-03-13 | ||||||||||
| 2025-09-30 | -$1.47M 10-Q · filed 2025-11-12 | ||||||||||
| 2025-06-30 | $139.01K 10-Q · filed 2026-08-07 | ||||||||||
| 2025-03-31 | $1.86M 10-Q · filed 2026-05-15 | ||||||||||
| 2024-12-31 | $6.54M 10-K · filed 2026-03-13 | ||||||||||
| 2024-09-30 | $699.07K 10-Q · filed 2025-11-12 | ||||||||||
| 2024-06-30 | $26.60K 10-Q · filed 2025-08-14 | ||||||||||
| 2024-03-31 | $279.62K 10-Q · filed 2025-05-15 | ||||||||||
| 2023-12-31 | -$2.83M 10-K · filed 2025-03-20 | ||||||||||
| 2023-09-30 | -$487.87K 10-Q · filed 2024-11-13 | ||||||||||
| 2023-06-30 | $926.81K 10-Q · filed 2024-08-12 | ||||||||||
| 2023-03-31 | $2.59M 10-Q · filed 2024-05-15 | ||||||||||
| 2022-12-31 | $3.60M 10-K · filed 2024-04-01 | $3.60M 10-K · filed 2023-03-31 | |||||||||
| 2022-09-30 | $8.45M 10-Q · filed 2023-11-13 | -$348.94K 10-Q · filed 2022-11-07 | |||||||||
| 2022-06-30 | $9.15M 10-Q · filed 2023-08-14 | -$481.04K 10-Q · filed 2022-08-10 | |||||||||
| 2022-03-31 | -$202.53K 10-Q · filed 2023-05-15 | -$146.01K 10-Q · filed 2022-05-12 | |||||||||
| 2021-12-31 | $526.63K 10-K · filed 2022-03-31 | $275.68K 10-K · filed 2023-03-31 | |||||||||
| 2021-09-30 | $9.68K 10-Q · filed 2022-11-07 | ||||||||||
| 2021-06-30 | $34.25K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |